September 7, 2023
Vesselon Town Hall Event Provides a Glimpse into the Future of Intravenous Drug Development
Industry experts reveal how Vesselon’s drug platform offers a new paradigm for extending patents and improving efficacy.
August 28, 2023
Vesselon Introduces the First On-site Co-formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs
By extending patents, the co-formulation and ultrasound activation at the clinic helps drug companies better manage product life cycles, protect franchises, differentiate their portfolios, and generate an endless stream of blockbusters.
May 22, 2023
Vesselon Discovery Protects and Expands Drug Franchises
Drug maker is seeking strategic relationship to deliver unprecedented levels of efficacy by making tissues more receptive to drugs.
September 25, 2021
Merck and Vesselon Preclinical Study Reports Dramatic Tumor Pharmacokinetics Findings
Complete regression of both primary and distant tumors in 44% of enrolled subjects achieved with intravenous administration.
August 7, 2019
Vesselon Acquires FDA Approved Lipid Microsphere Imagent
“By changing the rate of progression or stopping cancer in its tracks, Vesselon can change the cancer landscape.”
August 24, 2021
Sonoporation-Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression
Sonoporation, the temporal cell membrane openings that can arise after ultrasound exposure, has been explored across many preclinical applications but has lacked translational momentum.